Why the study?
Interleukin-6 levels and their prognostic value had not yet been investigated in cardiac transthyretin amyloidosis.
Do elevated interleukin-6 levels predict worse outcomes in patients with cardiac transthyretin amyloidosis?
Do elevated interleukin-6 levels predict worse outcomes in patients with cardiac transthyretin amyloidosis?
Answers are grounded in this paper and cite their sources.
While elevated IL-6 levels correlate with worse outcomes in ATTR-CM, they do not improve risk stratification beyond established prognostic factors.
BACKGROUND: Elevated interleukin (IL)-6-levels have been described in familial variant transthyretin amyloidosis (ATTRv) associated polyneuropathy and heart failure. However, IL-6 in cardiac ATTR amyloidosis (ATTR-CM) and its prognostic value have not been investigated yet. AIM: We aim to study the correlation between IL-6 levels with clinical presentation (Gillmore-class) and outcome [heart transplantation or death (htx/death)], or the combined endpoint of cardiac decompensation or htx/death in ATTR-CM. METHODS: IL-6 levels of 106 ATTR-CM patients [54 wild-type ATTRwt, 52 ATTRv-CM], 15 asymptomatic carriers of ATTR mutations (aATTRv-CM) and 27 healthy donors were quantified using Luminex technology. Statistical analysis was performed using parametric survival regression models. However, in the multivariate model, no significant improvement of risk prediction was seen for IL-6, while established prognostic factors were significantly associated with outcome. CONCLUSION: Raised IL-6 levels correlate with clinical presentation and are associated with worse outcome in ATTR-CM but do not improve stratification in addition to established risk factors.
No takes yet. Share an insight, caveat, or question.
Hein et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: